Gilead lifts guidance on HCV sales

Gilead Sciences Inc. (NASDAQ:GILD) reported $4.9 billion in HCV sales in 2Q15, up 41% from $3.5 billion in 2Q14. Sales of Harvoni ledipasvir/ sofosbuvir were $3.6 billion in 2Q15, while sales of Sovaldi sofosbuvir declined to $1.3 billion in 2Q15 from $3.5 billion in 2Q14.

Gilead raised its 2015 full year net product sales guidance to $29-$30 billion from its April guidance of $28-$29 billion. ...